4 results match your criteria: "Beijing Key Laboratory of Clinical Study on Anticancer Molecular Target Drugs[Affiliation]"
[The progress of diagnostic and prognostic molecular markers of lymphoma].
Zhonghua Xue Ye Xue Za Zhi
April 2015
Department of Medical Oncology, Cancer Institute/Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Target Drugs, Beijing 100021, China.
Sorafenib in metastatic radioactive iodine-refractory differentiated thyroid cancer: A pilot study.
Mol Clin Oncol
January 2014
Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China ; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Target Drugs, Beijing 100021, P.R. China.
The incidence and mortality of thyroid cancer are on the increase worldwide and the treatment options for progressive, radioactive iodine (RAI)-refractory metastatic differentiated thyroid cancer (DTC) patients are currently limited. Sorafenib is a multikinase inhibitor that targets several molecular signals, which are believed to be involved in the pathogenesis of DTC. In this study, we reported our experience with the off-label use of sorafenib in Chinese cancer patients.
View Article and Find Full Text PDFPegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study.
Anticancer Drugs
July 2013
Department of Medical Oncology, Cancer Institute/Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Target Drugs, Beijing, China.
The purpose of this study was to compare the efficacy and safety of a single subcutaneous injection of pegylated filgrastim with daily filgrastim as a prophylaxis for neutropenia induced by commonly used chemotherapy regimens. Fifteen centers enrolled 337 chemotherapy-naive cancer patients with normal bone marrow function. All patients randomized into AOB and BOA arms received two cycles of chemotherapy.
View Article and Find Full Text PDFDevelopment and validation of a rapid and sensitive UPLC-MS/MS method for determination of total docetaxel from a lipid microsphere formulation in human plasma.
J Chromatogr B Analyt Technol Biomed Life Sci
May 2013
Department of Medical Oncology, Cancer Institute/Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Target Drugs, 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, PR China.
Docetaxel lipid microsphere (DT-LM), an intravenous lipid emulsion for docetaxel without Tween 80, has demonstrated significant advantage over other conventional docetaxel formulations with respect to keeping sustained release, reducing irritation or toxicity of drug, sterile for intravenous injection and presenting targeting. A rapid, sensitive and reproducible ultra high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for determination of total docetaxel from a lipid microsphere formulation in human plasma using paclitaxel as internal standard (IS) has been developed and validated. The analytes and IS were extracted from plasma by simple liquid-liquid extraction and separated on ACQUITY UPLC BEH C18 column at a flow rate of 0.
View Article and Find Full Text PDF